Press releases
2023-11-17 07:58
THIRD QUARTER, JULY-SEPTEMBER 2023 JANUARY- SEPTEMBER 2023 Significant eventsDuring the reporting period After the reporting period Contacts About UsEmplicure uses patented bioceramic technology to develop innovative and effective products to help consumers...
2023-08-29 07:52
SECOND QUARTER, APRIL-JUNE 2023 JANUARY-JUNE 2023 SIGNIFICANT EVENTS This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the...
2023-05-09 07:58
FIRST QUARTER, JANUARY-MARCH 2023 From this report and onwards, Emplicure will present the quarterly financial reports in English only. This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation...
2023-02-23 08:05
FOURTH QUARTER, OCTOBER-DECEMBER 2022 JANUARY-DECEMBER 2022 This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency...
2022-11-17 07:55
THIRD QUARTER, JULY-SEPTEMBER 2022 JANUARY-SEPTEMBER 2022 For additional information, please contact Håkan Engqvist CEO Phone: +46 702 569 500 Email: hakan.engqvist@emplicure.com Erik Magnusson CFO Phone: +46 708 565 245 Email: erik.magnusson@emplicure.com...
2022-08-18 08:30
There is great interest in our unique patented bioceramic technology, which provides the opportunity to develop the next generation of nicotine pouches. Second quarter, April-June 2022 January-June 2022 This information is information that Emplicure AB...
2022-04-26 08:30
Our objective with Amp01 is to offer an enhanced customer experience through a significantly longer release profile of both nicotine and flavor, than what exists on the market today First quarter, 1 January - 31 March 2022 Torbjörn W. Larsson CEO...
2022-02-22 08:30
Fourth quarter, 1 October - 31 December 2021 · Net revenue totalled 0.0 (0.1) MSEK · EBIT totalled -5.2 (-1.6) MSEK · EBITDA totalled -5.1 (-1.6) MSEK · Cash flow totalled -4.6 (+0.6) MSEK ·...
2021-11-19 08:30
EMPLICURE INTERIM REPORT JANUARY-SEPTEMBER 2021 - BUILDING A STRONG TEAM AND A FOUNDATION FOR GROWTH
Following this summer's new share issue and subsequent IPO, we are well equipped. The focus of the third quarter has been on shifting up, and driving the development of the company's two main projects; Empli03, our drug candidate for chronic...